Vita Life SciencesASX:VLS +2.04%83 ROC (Joel Greenblatt) % is 75.66% as of Dec. 2025, which is 12% above its 10-year median of 67.48. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 975 Drug Manufacturers companies, Vita Life Sciences ranks better than 89.64% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vita Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 75.66%.
The historical rank and industry rank for Vita Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
ASX:VLS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 33.57 Med: 67.48 Max: 97.37
Current: 70.61
During the past 13 years, Vita Life Sciences's highest ROC (Joel Greenblatt) % was 97.37%. The lowest was 33.57%. And the median was 67.48%.
ASX:VLS's ROC (Joel Greenblatt) % is ranked better than 89.64% of 975
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs ASX:VLS: 70.61
Vita Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -2.90% per year.
Vita Life Sciences (ASX:VLS) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Vita Life Sciences ROC (Joel Greenblatt) % Related Terms
Vita Life Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VLS vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's ROC (Joel Greenblatt) % falls into.
Vita Life Sciences ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 75.66% mean?
Vita Life Sciences (ASX:VLS) has a ROC (Joel Greenblatt) % of 75.66% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vita Life Sciences and its competitors. This is 12% above median its historical median of 67.48. Over the past decade, Vita Life Sciences' ROC (Joel Greenblatt) % has ranged from 33.57 to 97.37. According to the industry distribution chart, Vita Life Sciences ranks #101 out of 975 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Vita Life Sciences' ROC (Joel Greenblatt) % too high?
Vita Life Sciences' current ROC (Joel Greenblatt) % of 75.66% is 12% above median its 10-year median of 67.48. Over the past 10 years, this metric has ranged from a low of 33.57 to a high of 97.37. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. Vita Life Sciences' value of 75.66% is 561.4% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #101 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #101 out of 975 companies for ROC (Joel Greenblatt) %. This places Vita Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.44. Vita Life Sciences' value of 75.66% is 561.4% above this benchmark. Historically, Vita Life Sciences' own ROC (Joel Greenblatt) % has ranged from 33.57 to 97.37 over the past decade. While the company's 10-year median is 67.48 vs. the industry median of 11.44, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current ROC (Joel Greenblatt) % of 75.66% is 561.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current ROC (Joel Greenblatt) % is 75.66%, which is 12% above median its own 10-year median of 67.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 75.66%, which is 12% above median its 10-year median of 67.48 and 561.4% above the Drug Manufacturers industry median of 11.44. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current ROC (Joel Greenblatt) % is 75.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
ROC (Joel Greenblatt) %: 75.66% (12% above median its 10-year median of 67.48)
GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
Industry Position: 561.4% above the Drug Manufacturers median (#101 of 975)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score
Get the complete analysis for ASX:VLS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
